once weekly glp 1 agonist Dosage of GLP-1 analogues GLP-1 Agonists—commonly used for weight

Phase 3 TRIUMPH trials and future dosing Retatrutide has not yet received regulatory approval

EMA statement on ongoing review of GLP-1 receptor agonists Internet Document

Medication is not available without a membership

Cardioprotective and Vasodilatory Actions of Glucagon-Like Peptide 1 Receptor Are Mediated Through Both Glucagon-Like Peptide 1 ReceptorDependent and Independent Pathways

Simic G, Babic Leko M, Wray S, Harrington C, Delalle I, Jovanov-Milosevic N, et al

JAMA Netw Open 7(8):e2423385 [DOI] [PMC free article] [PubMed] [Google Scholar] 85.Zhou J, Huang W, Xie Y, Shen H, Liu M, Wu X (2025) Risk of ophthalmic adverse drug reactions in patients prescribed glucagon-like peptide 1 receptor agonists: a pharmacovigilance study based on the FDA adverse event reporting system database